The Pfizer-backed cancer treatment developer, which initially floated in France in 2007, received $35m from Pfizer last year in return for a 10% stake.
Cellectis, a France-based gene-editing technology developer backed by pharmaceutical company Pfizer, filed for an initial public offering on Nasdaq on Friday in which it could raise up to $115m.
Cellectis is working on cancer treatments that use gene-edited T-cells to spur the immune system to target and eradicate cancers. Founded in 1999, it originally floated on the Alternext market in Paris in 2007.
Pfizer owns a 9.5% share of Cellectis, while state-backed investment firm BPIfrance holds a 10.4% stake. Pfizer…
